agilon health, inc.
AGLdata completeness 100%7 fiscal years on fileData notes: no data for concept 'epsDiluted'
agilon health, inc. earns about -337% on invested capital, but has diluted owners by 11% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $1.52B1 | $2.39B2 | $4.32B3 | $6.06B3 | $5.93B3 |
| Net income | −$406.5M4 | −$106.6M5 | −$262.6M6 | −$260.2M6 | −$391.3M6 |
| Operating cash flow | −$148.2M7 | −$130.8M8 | −$156.2M9 | −$57.8M9 | −$105.8M9 |
| Capital expenditure | $6.56M10 | $15.4M11 | $15.8M12 | $13.3M12 | $13.2M12 |
| Free cash flow (derived) | −$154.7M7 | −$146.2M8 | −$172M9 | −$71M9 | −$119M9 |
| Total debt | $97.2M13 | $87.2M14 | $77.1M15 | $34.9M16 | $70M16 |
| Cash & equivalents | $1.04B17 | $465.3M18 | $107.6M19 | $188.2M20 | $173.7M20 |
| Diluted shares | 372.9M | 408.2M | 408.9M | 411.0M | 414.0M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on $3.06 of net worth that earned you −$9.45 and generated −$2.87 of cash last year, against $1.69 of debt.
It earned an average -337% on invested capital over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is up 11% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has fallen 28% — deleveraging.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2021-12-31 · accession 0001628280-24-007242 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-12-31 · accession 0001628280-25-007721 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2023-12-31 · accession 0001628280-26-011655 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2021-12-31 · accession 0001628280-24-007242 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0001628280-25-007721 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001628280-26-011655 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0001628280-24-007242 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0001628280-25-007721 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001628280-26-011655 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0001628280-24-007242 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-12-31 · accession 0001628280-25-007721 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-12-31 · accession 0001628280-26-011655 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2021-12-31 · accession 0000950170-23-005541 (LongTermDebtNoncurrent)
- 10-K · period ending 2022-12-31 · accession 0001628280-24-007242 (LongTermDebtNoncurrent)
- 10-K · period ending 2023-12-31 · accession 0001628280-25-007721 (LongTermDebtNoncurrent)
- 10-K · period ending 2024-12-31 · accession 0001628280-26-011655 (LongTermDebtNoncurrent)
- 10-K · period ending 2021-12-31 · accession 0000950170-23-005541 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-12-31 · accession 0001628280-24-007242 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0001628280-25-007721 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-12-31 · accession 0001628280-26-011655 (CashAndCashEquivalentsAtCarryingValue)